Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% – Here’s Why

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares were up 5.7% during mid-day trading on Friday . The company traded as high as $157.35 and last traded at $156.2260. Approximately 45,524 shares traded hands during trading, a decline of 84% from the average daily volume of 282,512 shares. The stock had previously closed at $147.77.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PVLA. Stephens reissued an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital reiterated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, HC Wainwright raised their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Stock Performance

The business’s fifty day moving average price is $124.54 and its two-hundred day moving average price is $115.00. The stock has a market capitalization of $2.22 billion, a P/E ratio of -36.91 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts forecast that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds have recently added to or reduced their stakes in PVLA. KBC Group NV bought a new stake in shares of Palvella Therapeutics during the 1st quarter worth approximately $28,000. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the third quarter worth $36,000. JPMorgan Chase & Co. boosted its stake in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics in the second quarter worth about $85,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.